CN102552188A - 一种阿戈美拉汀片剂及制备方法、其包衣片剂及制备方法 - Google Patents
一种阿戈美拉汀片剂及制备方法、其包衣片剂及制备方法 Download PDFInfo
- Publication number
- CN102552188A CN102552188A CN2010105951024A CN201010595102A CN102552188A CN 102552188 A CN102552188 A CN 102552188A CN 2010105951024 A CN2010105951024 A CN 2010105951024A CN 201010595102 A CN201010595102 A CN 201010595102A CN 102552188 A CN102552188 A CN 102552188A
- Authority
- CN
- China
- Prior art keywords
- weight
- agomelatine
- tablet
- coating
- label
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 title claims abstract description 119
- 229960002629 agomelatine Drugs 0.000 title claims abstract description 119
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 229920002472 Starch Polymers 0.000 claims abstract description 68
- 235000019698 starch Nutrition 0.000 claims abstract description 68
- 239000008107 starch Substances 0.000 claims abstract description 68
- 239000011734 sodium Substances 0.000 claims abstract description 37
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 37
- 239000000314 lubricant Substances 0.000 claims abstract description 15
- 239000000945 filler Substances 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 239000011248 coating agent Substances 0.000 claims description 117
- 238000000576 coating method Methods 0.000 claims description 117
- 239000003826 tablet Substances 0.000 claims description 105
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 62
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 52
- 239000007788 liquid Substances 0.000 claims description 45
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 36
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 34
- 235000019359 magnesium stearate Nutrition 0.000 claims description 31
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 30
- 239000007864 aqueous solution Substances 0.000 claims description 30
- 239000008101 lactose Substances 0.000 claims description 30
- 239000000377 silicon dioxide Substances 0.000 claims description 30
- 235000012239 silicon dioxide Nutrition 0.000 claims description 28
- 239000007779 soft material Substances 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 24
- 239000008187 granular material Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 20
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 15
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 15
- 239000011230 binding agent Substances 0.000 claims description 14
- 239000007921 spray Substances 0.000 claims description 12
- 239000008188 pellet Substances 0.000 claims description 11
- 239000007941 film coated tablet Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 239000000853 adhesive Substances 0.000 abstract description 2
- 230000001070 adhesive effect Effects 0.000 abstract description 2
- 229960001375 lactose Drugs 0.000 description 26
- 229920003081 Povidone K 30 Polymers 0.000 description 22
- 238000012056 up-stream process Methods 0.000 description 22
- 238000005303 weighing Methods 0.000 description 21
- 239000002671 adjuvant Substances 0.000 description 18
- 239000008213 purified water Substances 0.000 description 16
- 229940032147 starch Drugs 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 8
- 238000007664 blowing Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 238000012154 short term therapy Methods 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- UUXLZQRTGHEMET-UHFFFAOYSA-N COC1=CC=C2C=CC=C(C2=C1)CCNC(C)=O.C(C)(=O)N Chemical compound COC1=CC=C2C=CC=C(C2=C1)CCNC(C)=O.C(C)(=O)N UUXLZQRTGHEMET-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101150013372 Htr2c gene Proteins 0.000 description 1
- 229940121723 Melatonin receptor agonist Drugs 0.000 description 1
- 102100024930 Melatonin receptor type 1A Human genes 0.000 description 1
- 101710098568 Melatonin receptor type 1A Proteins 0.000 description 1
- 102100024970 Melatonin receptor type 1B Human genes 0.000 description 1
- 101710098567 Melatonin receptor type 1B Proteins 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 108010060469 mesotocin receptor Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
检查项目 | 处方1 | 处方2 | 处方3 | 处方4 | 处方5 | 处方6 |
颗粒外观 | 均匀 | 均匀 | 均匀 | 均匀 | 均匀 | 均匀 |
休止角(°) | 38.66 | 35.93 | 36.87 | 35.93 | 34.01 | 33.02 |
片芯硬度(kg) | 5.10 | 4.77 | 7.63 | 7.07 | 8.14 | 8.21 |
片子外观 | 光洁 | 光洁 | 光洁 | 光洁 | 光洁 | 光洁 |
崩解时限(min) | 5 | 5 | 4 | 3 | 3 | 3 |
脆碎度(%) | 有裂片 | 有裂片 | 0.39 | 0.42 | 0.37 | 0.45 |
片重差异(%) | - | - | -3.5~3.2 | -3.5~3.4 | -3.8~3.2 | -3.4~3.6 |
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010595102 CN102552188B (zh) | 2010-12-17 | 2010-12-17 | 一种阿戈美拉汀片剂及制备方法、其包衣片剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010595102 CN102552188B (zh) | 2010-12-17 | 2010-12-17 | 一种阿戈美拉汀片剂及制备方法、其包衣片剂及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102552188A true CN102552188A (zh) | 2012-07-11 |
CN102552188B CN102552188B (zh) | 2013-12-25 |
Family
ID=46399656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010595102 Expired - Fee Related CN102552188B (zh) | 2010-12-17 | 2010-12-17 | 一种阿戈美拉汀片剂及制备方法、其包衣片剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102552188B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103251567A (zh) * | 2013-06-05 | 2013-08-21 | 重庆华森制药有限公司 | 一种阿戈美拉汀片剂及其制备方法 |
CN103655499A (zh) * | 2013-12-23 | 2014-03-26 | 天津泰普药品科技发展有限公司 | 一种稳定的晶x型阿戈美拉汀片剂及其制备方法 |
CN104873470A (zh) * | 2015-02-10 | 2015-09-02 | 济南利民制药有限责任公司 | 阿戈美拉汀片剂、薄膜包衣片剂及其制备方法 |
CN105579065A (zh) * | 2013-06-06 | 2016-05-11 | 赞蒂瓦有限合伙公司 | 包含呈共晶体形式的阿戈美拉汀的阿戈美拉汀制剂 |
CN106727375A (zh) * | 2016-12-21 | 2017-05-31 | 江苏豪森药业集团有限公司 | 阿戈美拉汀片剂及其制备方法 |
CN106880610A (zh) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | 一种雷美替胺分散片及其制备方法 |
EP3087977A4 (en) * | 2013-12-23 | 2017-08-02 | Tianjin Taipu Pharmaceutical Science & Technology Development Co., Ltd. | Stable crystal i-form agomelatine tablet and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732296A (zh) * | 2009-12-30 | 2010-06-16 | 北京德众万全药物技术开发有限公司 | 一种含有阿戈美拉汀的药用组合物 |
-
2010
- 2010-12-17 CN CN 201010595102 patent/CN102552188B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732296A (zh) * | 2009-12-30 | 2010-06-16 | 北京德众万全药物技术开发有限公司 | 一种含有阿戈美拉汀的药用组合物 |
Non-Patent Citations (1)
Title |
---|
毕殿洲: "《药剂学》", 28 February 2003, 人民卫生出版社 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103251567A (zh) * | 2013-06-05 | 2013-08-21 | 重庆华森制药有限公司 | 一种阿戈美拉汀片剂及其制备方法 |
CN103251567B (zh) * | 2013-06-05 | 2014-03-12 | 重庆华森制药有限公司 | 一种阿戈美拉汀片剂及其制备方法 |
CN105579065A (zh) * | 2013-06-06 | 2016-05-11 | 赞蒂瓦有限合伙公司 | 包含呈共晶体形式的阿戈美拉汀的阿戈美拉汀制剂 |
CN105579065B (zh) * | 2013-06-06 | 2018-11-16 | 赞蒂瓦有限合伙公司 | 包含呈共晶体形式的阿戈美拉汀的阿戈美拉汀制剂 |
CN103655499A (zh) * | 2013-12-23 | 2014-03-26 | 天津泰普药品科技发展有限公司 | 一种稳定的晶x型阿戈美拉汀片剂及其制备方法 |
EP3087976A4 (en) * | 2013-12-23 | 2017-08-02 | Tianjin Taipu Pharmaceutical Science & Technology Development Co., Ltd. | Stable crystal x-form agomelatine tablet and preparation method thereof |
EP3087977A4 (en) * | 2013-12-23 | 2017-08-02 | Tianjin Taipu Pharmaceutical Science & Technology Development Co., Ltd. | Stable crystal i-form agomelatine tablet and preparation method thereof |
CN104873470A (zh) * | 2015-02-10 | 2015-09-02 | 济南利民制药有限责任公司 | 阿戈美拉汀片剂、薄膜包衣片剂及其制备方法 |
CN106880610A (zh) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | 一种雷美替胺分散片及其制备方法 |
CN106727375A (zh) * | 2016-12-21 | 2017-05-31 | 江苏豪森药业集团有限公司 | 阿戈美拉汀片剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102552188B (zh) | 2013-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102552188B (zh) | 一种阿戈美拉汀片剂及制备方法、其包衣片剂及制备方法 | |
WO2013054872A1 (ja) | 7-[4-(4-ベンゾ[b]チオフェン-4-イル-ピペラジン-1-イル)ブトキシ]-1H-キノリン-2-オン又はその塩を含む錠剤 | |
CN102740893B (zh) | 压制包衣的口腔崩解片剂 | |
EP3981399A1 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
CN106389360A (zh) | 盐酸达泊西汀直压片及其制备方法 | |
CN104116741B (zh) | 盐酸维拉佐酮组合物及其制备方法 | |
CN103768063B (zh) | 一种盐酸莫西沙星药物组合物及其制备方法 | |
CN113230225B (zh) | 一种阿托伐他汀钙片及其制备方法与用途 | |
CN106139156B (zh) | 一种含有喹啉衍生物或其盐的药物组合物 | |
CN103251567B (zh) | 一种阿戈美拉汀片剂及其制备方法 | |
CN109498587A (zh) | 盐酸鲁拉西酮片的制备方法 | |
CN107648191B (zh) | 一种氯雷他定片及其制备工艺 | |
CN103565773A (zh) | 一种盐酸普拉格雷的药物组合物 | |
CN107982237B (zh) | 一种盐酸索他洛尔制剂及其制备方法 | |
TW201916881A (zh) | 一種含有喹啉衍生物的藥物組合物 | |
CN106913544B (zh) | 一种快速溶出的吉非替尼片剂及其制备方法 | |
CN106994121A (zh) | 一种用于治疗癌症的药物组合物 | |
CN106074415B (zh) | 一种阿立哌唑片剂及其制备方法 | |
CN105434375A (zh) | 一种左乙拉西坦片剂及制备方法 | |
CN103690499B (zh) | 一种稳定的晶i型阿戈美拉汀片剂及其制备方法 | |
CN111481568B (zh) | 一种铝碳酸镁片及其制备工艺 | |
CN104055741A (zh) | 一种孟鲁司特钠片剂及其制备方法 | |
CN110354093B (zh) | 一种枸橼酸莫沙必利药物组合物 | |
CN103655499B (zh) | 一种稳定的晶x型阿戈美拉汀片剂及其制备方法 | |
CN103127108A (zh) | 替米沙坦氨氯地平片及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 100871, Beijing, Haidian District Cheng Fu Road 298, founder building, 9 floor Patentee after: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: PKU HEALTHCARE INDUSTRY Group Address before: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: Pku Healthcare Industry Group Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221018 Address after: 3007, Hengqin international financial center building, No. 58, Huajin street, Hengqin new area, Zhuhai, Guangdong 519031 Patentee after: New founder holdings development Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: Peking University Medical Management Co.,Ltd. Address before: 100871, Beijing, Haidian District Cheng Fu Road 298, founder building, 9 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: PKU HEALTHCARE INDUSTRY Group |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131225 |